Raymond Winquist - Net Worth and Insider Trading
Raymond Winquist Net Worth
The estimated net worth of Raymond Winquist is at least $35,310 dollars as of 2025-03-23. Raymond Winquist is the Head, Translational Research of Xenon Pharmaceuticals Inc and owns about 1,000 shares of Xenon Pharmaceuticals Inc (XENE) stock worth over $35,310. Details can be seen in Raymond Winquist's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Raymond Winquist has not made any transactions after 2017-08-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Raymond Winquist
Raymond Winquist Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Raymond Winquist owns 1 companies in total, including Xenon Pharmaceuticals Inc (XENE) .
Click here to see the complete history of Raymond Winquist’s form 4 insider trades.
Insider Ownership Summary of Raymond Winquist
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc | 2017-08-18 | Head & Translational Research |
Raymond Winquist Latest Holdings Summary
Raymond Winquist currently owns a total of 1 stock. Raymond Winquist owns 1,000 shares of Xenon Pharmaceuticals Inc (XENE) as of August 18, 2017, with a value of $35,310.
Latest Holdings of Raymond Winquist
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc | 2017-08-18 | 1,000 | 35.31 | 35,310 |
Holding Weightings of Raymond Winquist
Raymond Winquist Form 4 Trading Tracker
According to the SEC Form 4 filings, Raymond Winquist has made a total of 0 transactions in Xenon Pharmaceuticals Inc (XENE) over the past 5 years. The most-recent trade in Xenon Pharmaceuticals Inc is the acquisition of 1,000 shares on August 18, 2017, which cost Raymond Winquist around $3,000.
Insider Trading History of Raymond Winquist
- 1
Raymond Winquist Trading Performance
GuruFocus tracks the stock performance after each of Raymond Winquist's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Raymond Winquist is -18.64%. GuruFocus also compares Raymond Winquist's trading performance to market benchmark return within the same time period. The performance of stocks bought by Raymond Winquist within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Raymond Winquist's insider trading performs compared to the benchmark.
Performance of Raymond Winquist
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 3.39 | | | | | |
| Relative Return to S&P 500(%) | 0.16 | | | | | |
Raymond Winquist Ownership Network
Ownership Network List of Raymond Winquist
Ownership Network Relation of Raymond Winquist
Raymond Winquist Owned Company Details
What does Xenon Pharmaceuticals Inc do?
Who are the key executives at Xenon Pharmaceuticals Inc?
Raymond Winquist is the Head & Translational Research of Xenon Pharmaceuticals Inc. Other key executives at Xenon Pharmaceuticals Inc include director & PRESIDENT & CEO Ian Mortimer , Chief Financial Officer Sherry Aulin , and SVP Bus. & Corp. Development Sherrington Robin .
Xenon Pharmaceuticals Inc (XENE) Insider Trades Summary
Over the past 18 months, Raymond Winquist made no insider transaction in Xenon Pharmaceuticals Inc (XENE). Other recent insider transactions involving Xenon Pharmaceuticals Inc (XENE) include a net sale of 31,467 shares made by Gary Patou , a net sale of 55,000 shares made by Ian Mortimer , and a net sale of 18,709 shares made by Sherry Aulin .
In summary, during the past 3 months, insiders sold 55,000 shares of Xenon Pharmaceuticals Inc (XENE) in total and bought 0 shares, with a net sale of 55,000 shares. During the past 18 months, 127,405 shares of Xenon Pharmaceuticals Inc (XENE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 127,405 shares.
Xenon Pharmaceuticals Inc (XENE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Xenon Pharmaceuticals Inc Insider Transactions
Raymond Winquist Mailing Address
Above is the net worth, insider trading, and ownership report for Raymond Winquist. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Raymond Winquist's mailing address is: Burnaby A0 V5g 48w.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
